{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-bimo-inspection-preparation-and-response-strategy-fda-specific”
},
“headline”: “SOP for BIMO Inspection Preparation and Response Strategy (FDA Specific)”,
“description”: “This SOP outlines procedures for preparing for and responding to FDA Bioresearch Monitoring (BIMO) inspections. It covers sponsor, CRO, and investigator responsibilities, pre-inspection readiness, conduct during inspection, handling Form 483s, CAPA planning, and record archiving.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for BIMO Inspection Preparation and Response Strategy (FDA Specific)

Purpose

The purpose of this SOP is to establish a standardized process for preparing for, managing, and responding to FDA Bioresearch Monitoring (BIMO) inspections. These inspections ensure protection of human subjects, data integrity, and compliance with regulatory requirements under FDA oversight.

Scope

This SOP applies to sponsors, CROs, investigators, QA teams, and regulatory affairs personnel engaged in U.S. IND clinical trials subject to BIMO inspections. It includes pre-inspection readiness, inspection conduct, communication with inspectors, post-inspection follow-up, and CAPA management.

Responsibilities

• Sponsor: Ensures inspection readiness across all sites and maintains oversight of documentation.
• Investigator: Ensures site-level compliance, staff training, and availability of source records.
• CRO: Provides support for inspection preparation, document retrieval, and site coordination.
• Regulatory Affairs: Manages FDA communications and official responses.
• QA: Conducts mock inspections, audits, and CAPA oversight.

Accountability

The Sponsor’s QA Director is accountable for FDA BIMO inspection readiness and remediation. Investigators are accountable for site-level preparation and subject protection during inspections.

Procedure

1. Pre-Inspection Preparation
1.1 Conduct mock inspections quarterly.
1.2 Verify TMF and ISF completeness and accuracy.
1.3 Train staff on inspection conduct.
1.4 Document in Pre-Inspection Readiness Log (Annexure-1).

2. Notification and Planning
2.1 Upon FDA notification, establish an inspection response team.
2.2 Inform site staff, CRO, and investigators.
2.3 Record in Inspection Notification Log (Annexure-2).

3. Conduct During Inspection
3.1 Ensure inspectors have access to requested documents promptly.
3.2 Maintain an Inspection Document Log (Annexure-3).
3.3 Record all inspector queries in an Inspector Query Log (Annexure-4).

4. FDA Form 483 Handling
4.1 Review Form 483 observations immediately.
4.2 Draft response within 15 business days.
4.3 Record in FDA 483 Response Log (Annexure-5).

5. CAPA Implementation
5.1 Develop CAPA plan for identified deficiencies.
5.2 Implement corrective measures at sponsor, CRO, and site levels.
5.3 Document in CAPA Log (Annexure-6).

6. Post-Inspection Follow-Up
6.1 Submit final remediation updates to FDA.
6.2 Archive inspection materials in TMF/ISF.
6.3 Record in Inspection Follow-Up Log (Annexure-7).

Abbreviations

• SOP: Standard Operating Procedure
• BIMO: Bioresearch Monitoring
• FDA: Food and Drug Administration
• IND: Investigational New Drug
• CRO: Contract Research Organization
• QA: Quality Assurance
• TMF: Trial Master File
• ISF: Investigator Site File
• CAPA: Corrective and Preventive Action

Documents

1. Pre-Inspection Readiness Log (Annexure-1)
2. Inspection Notification Log (Annexure-2)
3. Inspection Document Log (Annexure-3)
4. Inspector Query Log (Annexure-4)
5. FDA 483 Response Log (Annexure-5)
6. CAPA Log (Annexure-6)
7. Inspection Follow-Up Log (Annexure-7)

References

• FDA – Bioresearch Monitoring Program
• 21 CFR Part 312 – IND Regulations
• ICH GCP E6(R2)

Version: 1.0

Approval Section

Annexures

Annexure-1: Pre-Inspection Readiness Log

Annexure-2: Inspection Notification Log

Annexure-3: Inspection Document Log

Annexure-4: Inspector Query Log

Annexure-5: FDA 483 Response Log

Annexure-6: CAPA Log

Annexure-7: Inspection Follow-Up Log

Revision History

For more SOPs visit: Pharma SOP